Change and Innovation
BioPharm International is the longest-running peer-reviewed publication dedicated to your work.
Recently we announced the appointment of Michelle Hoffman as Editorial Director of Advanstar's Pharmaceutical Drug Development and Manufacturing Group, which now includes BioPharm International, Pharmaceutical Technology, Pharmaceutical Technology Europe, and the IVT Journals. I am pleased to join Ms. Hoffman as BioPharm International's new publisher.
Allen Basis
It is exciting to work with an editor whose curriculum vita matches our tagline, "The Science & Business of Pharmaceuticals." Michelle's appointment and my employment and dedication to BioPharm International are examples of an evolving list of investments Advanstar Communications, our parent, is making in the brand. With more than 20 years of media management, I am dedicated to developing new and innovative ways of delivering the content you've come to depend on in print and online.
BioPharm International is the longest-running peer-reviewed publication dedicated to facilitating your work in the development and manufacturing of biotherapeutics and managing related business issues. Our goal is to provide the most up-to-date, reliable, and insightful information available to you in the biopharmaceutical market. To ensure that we meet your needs, I will seek your opinions about our performance.
We strive to equip you to manage your technical and business challenges effectively, but if we can serve you better with more news and information on tools, techniques, or business, we invite you to please let us know. Please drop us a line and be sure to look for us at industry conferences and expos throughout the year.
All the best,
Allen Basis is the publisher of BioPharm International, abasis@advanstar.com.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
